HIND Key Statistics, Chart & Performance
The current stock price of HIND is 4.955 USD. In the past month the price decreased by -21.47%.
HIND Latest News, Press Relases and Analysis
HIND Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.31 | 219.65B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.94 | 201.26B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.57 | 146.79B | ||
| SYK | STRYKER CORP | 27.84 | 140.23B | ||
| IDXX | IDEXX LABORATORIES INC | 58.11 | 58.51B | ||
| BDX | BECTON DICKINSON AND CO | 13.21 | 54.59B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.96 | 49.16B | ||
| RMD | RESMED INC | 25.34 | 36.62B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.48 | 36.54B | ||
| DXCM | DEXCOM INC | 34.65 | 25.14B | ||
| PODD | INSULET CORP | 67.61 | 21.74B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.64 | 18.66B |
Related stock screener links
About HIND
Company Profile
Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Company Info
VYOME HOLDINGS INC
1001 Calle Amanecer
San Clemente CALIFORNIA US
Employees: 17
Phone: 19494296680
VYOME HOLDINGS INC / HIND FAQ
Can you describe the business of VYOME HOLDINGS INC?
Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
What is the current price of HIND stock?
The current stock price of HIND is 4.955 USD. The price increased by 0.2% in the last trading session.
Does HIND stock pay dividends?
HIND does not pay a dividend.
What is the ChartMill technical and fundamental rating of HIND stock?
HIND has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for HIND stock?
6 analysts have analysed HIND and the average price target is 15.3 USD. This implies a price increase of 208.78% is expected in the next year compared to the current price of 4.955.
Can you provide the upcoming earnings date for VYOME HOLDINGS INC?
VYOME HOLDINGS INC (HIND) will report earnings on 2026-04-02, after the market close.
What is the ownership structure of VYOME HOLDINGS INC (HIND)?
You can find the ownership structure of VYOME HOLDINGS INC (HIND) on the Ownership tab.
HIND Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HIND.
HIND Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HIND. The financial health of HIND is average, but there are quite some concerns on its profitability.
HIND Financial Highlights
Over the last trailing twelve months HIND reported a non-GAAP Earnings per Share(EPS) of -490.67. The EPS increased by 93.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.82% | ||
| ROE | -77.17% | ||
| Debt/Equity | 0 |
HIND Forecast & Estimates
6 analysts have analysed HIND and the average price target is 15.3 USD. This implies a price increase of 208.78% is expected in the next year compared to the current price of 4.955.
For the next year, analysts expect an EPS growth of 6.67% and a revenue growth -97.51% for HIND